Teva Pharmaceutical Industries (TEVA) Stock Analysis

By Naomi Wentworth • Friday, May 30 09:55 • Permanent Link

One of the losers of today's trading session was Teva Pharmaceutical Industries. Shares of the Pharmaceutical company plunged -2.7%, and some investors may be wondering if its price of $17.05 would make a good entry point. Here's what you should know if you are considering this investment:

Teva Pharmaceutical Industries has moved 3.5% over the last year, and the S&P 500 logged a change of 12.0%
TEVA has an average analyst rating of buy and is -26.23% away from its mean target price of $23.12 per share
Its trailing earnings per share (EPS) is $-1.15
Teva Pharmaceutical Industries has a trailing 12 month Price to Earnings (P/E) ratio of -14.8 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $2.77 and its forward P/E ratio is 6.2
The company has a Price to Book (P/B) ratio of 3.12 in contrast to the S&P 500's average ratio of 4.74
Teva Pharmaceutical Industries is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
The company has a free cash flow of $1.66 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.